BRPI0414679A - uso de antagonistas de receptor npy y5 para tratamento de distúrbios do ritmo circadiano - Google Patents
uso de antagonistas de receptor npy y5 para tratamento de distúrbios do ritmo circadianoInfo
- Publication number
- BRPI0414679A BRPI0414679A BRPI0414679-4A BRPI0414679A BRPI0414679A BR PI0414679 A BRPI0414679 A BR PI0414679A BR PI0414679 A BRPI0414679 A BR PI0414679A BR PI0414679 A BRPI0414679 A BR PI0414679A
- Authority
- BR
- Brazil
- Prior art keywords
- npy
- circadian rhythm
- treatment
- receptor antagonists
- rhythm disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DE ANTAGONISTAS DO RECEPTOR NPY Y5 PARA TRATAMENTO DE DISTúRBIOS DO RITMO CIRCADIANO". Método para o tratamento das distúrbios do ritmo circadiano em mamíferos, compreendendo a administração, a um mamífero, de uma quantidade eficaz de um antagonista do receptor de NPY Y5. Em particular, é proporcionado um método para intensificar os efeitos da luz sobre o ritmo circadiano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50624603P | 2003-09-26 | 2003-09-26 | |
PCT/IB2004/002996 WO2005030208A1 (en) | 2003-09-26 | 2004-09-13 | Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414679A true BRPI0414679A (pt) | 2006-11-28 |
Family
ID=34393127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414679-4A BRPI0414679A (pt) | 2003-09-26 | 2004-09-13 | uso de antagonistas de receptor npy y5 para tratamento de distúrbios do ritmo circadiano |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050119283A1 (pt) |
EP (1) | EP1670468A1 (pt) |
JP (1) | JP2007506728A (pt) |
BR (1) | BRPI0414679A (pt) |
CA (1) | CA2540190A1 (pt) |
MX (1) | MXPA06003380A (pt) |
TW (1) | TW200524920A (pt) |
WO (1) | WO2005030208A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591768A (en) * | 1990-12-04 | 1997-01-07 | State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Methods for treating circadian rhythm phase disturbances |
US5703239A (en) * | 1995-06-02 | 1997-12-30 | Bristol-Myers Squibb Company | Indanylpiperidines as melatonergic agents |
JP2000515018A (ja) * | 1996-07-18 | 2000-11-14 | ザ ジェネラル ホスピタル コーポレーション | メラトニン1aレセプター遺伝子調節領域およびその使用 |
AU2935200A (en) * | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
JP2004520299A (ja) * | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | スピロ[イソベンゾフラン−1,4’−ピペリジン]−3−オン類及び3h−スピロイソベンゾフラン−1,4’−ピペリジン類 |
CA2469790A1 (en) * | 2001-12-17 | 2003-06-26 | Merck & Co., Inc. | Method for treating circadian rhythm disruptions |
-
2004
- 2004-09-13 CA CA002540190A patent/CA2540190A1/en not_active Abandoned
- 2004-09-13 BR BRPI0414679-4A patent/BRPI0414679A/pt not_active IP Right Cessation
- 2004-09-13 WO PCT/IB2004/002996 patent/WO2005030208A1/en not_active Application Discontinuation
- 2004-09-13 MX MXPA06003380A patent/MXPA06003380A/es unknown
- 2004-09-13 EP EP04769382A patent/EP1670468A1/en not_active Withdrawn
- 2004-09-13 JP JP2006527504A patent/JP2007506728A/ja active Pending
- 2004-09-24 TW TW093129059A patent/TW200524920A/zh unknown
- 2004-09-27 US US10/951,325 patent/US20050119283A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2007506728A (ja) | 2007-03-22 |
WO2005030208A1 (en) | 2005-04-07 |
EP1670468A1 (en) | 2006-06-21 |
CA2540190A1 (en) | 2005-04-07 |
US20050119283A1 (en) | 2005-06-02 |
TW200524920A (en) | 2005-08-01 |
MXPA06003380A (es) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111177T1 (el) | Ενωση φαινοθειαζινιου για επουλωση τραυματων | |
BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
BR112012010027A2 (pt) | dispositivo para uso pessoal em uma fototerapia | |
CU23226B7 (es) | COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS | |
UY27939A1 (es) | Compuestos | |
EA201000211A1 (ru) | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения | |
EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
BR0310099A (pt) | método para tratar dislipidemia ou uma doença associada com a dislipidemia | |
PT1135153E (pt) | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares | |
EA200300183A1 (ru) | Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
CY1115550T1 (el) | Λαμινινη (lαμινiν)-1 για χρηση στην αυξηση της αναγεννησης μυων ή για βελτιωση της ιασης τραυματος που χορηγειται συστημικα | |
DE69720745D1 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
BRPI0415709A (pt) | esquemas terapêuticos para antagonistas de baff | |
BR0215404A (pt) | processo e dispositivo para reduzir dosagem terapêutica | |
DK1450811T3 (da) | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf | |
BR0115162A (pt) | Tratamentos antitumorais eficazes | |
EE05315B1 (et) | Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette nhtud imetajal esineva seksuaalse funktsioonihire ravimiseks v?i m?jutamiseks | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
WO2003072049A3 (en) | Induction of hair growth with vascular endothelial growth factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |